Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
Conditions: Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor Along With Microsatellite Stable (MSS) Colon Cancer; Colon Cancer Interventions: Drug: Copanlisib; Drug: Nivolumab Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Bayer; Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Colon Cancer | Colorectal Cancer | Gastroschisis Repair | Research | Study